GSK awarded contract by BARDA to support research on potential novel antibiotic
- Details
- Category: GlaxoSmithKline
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
Bayer Confident in Results of ROCKET AF Study
- Details
- Category: Bayer
A Cardiovascular and Renal Drugs Advisory Committee meeting has been scheduled for September 8, 2011, to review the New Drug Application in the USA for rivaroxaban in the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe.
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
- Details
- Category: Novartis
Novartis announced today that the European Commission has approved Afinitor® (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease[3].
AstraZeneca announces top-line results from SATURN study
- Details
- Category: AstraZeneca
AstraZeneca today announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.
Bayer Healthcare to acquire Pathway Medical Technologies
- Details
- Category: Bayer
Bayer HealthCare announced today that its affiliate, MEDRAD, Inc. has acquired Pathway Medical Technologies, Inc., of Kirkland, Wash. Financial terms of the agreement were not disclosed. With this acquisition, Bayer HealthCare is strengthening its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies.
Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the start of a synergistic initiative to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania as part of their global social contribution activities.
More Pharma News ...
- €1 Million Awarded to Winning Projects
- Additional Analyses from PLATO Presented at ESC Congress
- U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib)
- Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
- Novo Nordisk to build new corporate centre in Bagsværd, Denmark
- FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
- FDA Grants Fast Track Designation to Bayer's Investigational Compound Alpharadin™